Payment overview · 2025
General Payments
$36.97
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brian P Ragona, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · JOLIET, IL · NPI 1992701015
Verified facts
What the public records show
CMS Open Payments records show Brian P Ragona, M.D. received $36.97 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 59.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.09 | 59.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.88 | 40.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $36.97 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 456 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 37 |
| Losartan Potassium | Losartan Potassium | 243 | 72 |
| Metformin Hcl | Metformin Hcl | 235 | 69 |
| Alprazolam | Alprazolam | 229 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 66 |
| Omeprazole | Omeprazole | 185 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 50 |
| Simvastatin | Simvastatin | 162 | 48 |
| Lisinopril | Lisinopril | 161 | 42 |
| Furosemide | Furosemide | 157 | 54 |
| Potassium Chloride | Potassium Chloride | 157 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 40 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 121 | 12 |
| Clonazepam | Clonazepam | 120 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 34 |
| Gabapentin | Gabapentin | 103 | 35 |
| Carvedilol | Carvedilol | 96 | 32 |
| Irbesartan | Irbesartan | 82 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 23 |
| Ozempic | Semaglutide | 79 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 24 |
| Meloxicam | Meloxicam | 76 | 28 |
| Pregabalin | Pregabalin | 72 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 21 |
| Tramadol Hcl | Tramadol Hcl | 66 | 16 |
| Lorazepam | Lorazepam | 65 | 13 |
| Finasteride | Finasteride | 64 | 18 |
| Prednisone | Prednisone | 64 | 37 |
| Allopurinol | Allopurinol | 63 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 19 |
| Eliquis | Apixaban | 59 | 17 |
| Trazodone Hcl | Trazodone Hcl | 57 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 16 |
| Montelukast Sodium | Montelukast Sodium | 50 | 18 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 13 |
| Famotidine | Famotidine | 45 | 14 |
| Glipizide Er | Glipizide | 45 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Januvia | Sitagliptin Phosphate | 43 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Atenolol | Atenolol | 41 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 20 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 11 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Invokana | Canagliflozin | 38 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 22 |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Diazepam | Diazepam | 33 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 33 | 14 |
| Buprenorphine Hcl | Buprenorphine Hcl | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 30 | 11 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Topiramate | Topiramate | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 11 |
| Temazepam | Temazepam | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 11 |
| Nabumetone | Nabumetone | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Repatha Pushtronex | Evolocumab | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Cefadroxil | Cefadroxil | 15 | 11 |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36.97 · 2 records | Lilly USA, LLC | FARXIGA, MOUNJARO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error